Unveiling the Potential Drug Target UCP2: A Sucrose Neuron Model for the Treatment of neurological Disorders

Target Name: UCP2

NCBI ID: G7351

UCP2

Unveiling the Potential Drug Target UCP2: A Sucrose Neuron Model for the Treatment of neurological Disorders

Uncovering new drug targets is a critical aspect of drug development, and the search for new therapeutic approaches is ongoing. One of the promising targets in the field of neurology is the Uncoiled Proteins (UCP) family, which plays a crucial role in the regulation of cell signaling pathways. UCP2, a member of the UCP family, has been identified as a potential drug target and has been shown to contribute to the development of various neurological disorders. In this article, we will explore the current research on UCP2 and highlight its potential as a drug target.

Overview of UCP2

UCP2 is a 21-kDa protein that belongs to the Uncoiled Proteins family. It is highly conserved across various species, including humans, and is involved in various cellular processes, including cell signaling, protein folding, and regulatory interactions. UCP2 functions as a scaffold protein, playing a critical role in the regulation of actinin, a protein that is involved in the cytoskeleton and cell signaling.

In neuroscience, UCP2 has been shown to be involved in the development and progression of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Studies have shown that UCP2 levels are decreased in the brains of individuals with these disorders, and overexpression of UCP2 has been shown to exacerbate the symptoms of these disorders.

Drug Target Potential

The potential drug target for UCP2 is based on its involvement in the regulation of cellular signaling pathways and its role in the development of neurological disorders. Several drug compounds have been shown to interact with UCP2 and to modulate its activity. These drugs include small molecules, peptides, and proteins that can either activate or inhibit the activity of UCP2.

One of the most promising drug targets for UCP2 is the use of small molecules that can inhibit the activity of UCP2 and improve the expression of UCP2. For instance, a study by Zhang et al. found that the inhibition of UCP2 using the small molecule drug BMY-2177 improved the expression of UCP2 and reduced the levels of UCP2 in rat brains, leading to improved cognitive function.

Another approach to targeting UCP2 is the use of peptides that can specifically interact with UCP2 and modulate its activity. For example, a study by Wang et al. found that the use of a specific peptide, called P12, improved the expression of UCP2 and reduced the levels of UCP2 in mouse brains, leading to improved memory and learning abilities.

In addition to small molecules and peptides, the use of proteins that can interact with UCP2 and modulate its activity is also being explored as a potential drug target. For instance, a study by Zhao et al. found that the use of the protein antagonist FAK inhibitor 1502 improved the expression of UCP2 and reduced the levels of UCP2 in human cancer cells, leading to the inhibition of cell signaling pathways.

Current Research and Therapeutic Applications

Current research on UCP2 is focused on the development of new therapeutic approaches that can modulate its activity and improve the expression of UCP2 in various neurological disorders.

One of the most promising approaches is the use of small molecules that can inhibit the activity of UCP2 and improve the expression of UCP2. Studies have shown that the use of small molecules that can interact with UCP2, such as BMY-2177, can improve the expression of UCP2 and reduce the levels of UCP2 in various neurological disorders.

Another promising approach is the use of peptides that can specifically interact with UCP2 and

Protein Name: Uncoupling Protein 2

Functions: Antiporter that exports dicarboxylate intermediates of the Krebs cycle in exchange for phosphate plus a proton across the inner membrane of mitochondria, a process driven by mitochondrial motive force with an overall impact on glycolysis, glutaminolysis and glutathione-dependent redox balance. Continuous export of oxaloacetate and related four-carbon dicarboxylates from mitochondrial matrix into the cytosol negatively regulates the oxidation of acetyl-CoA substrates via the Krebs cycle lowering the ATP/ADP ratio and reactive oxygen species (ROS) production (PubMed:24395786). Proton transporter activity is debated, but if it occurs it may mediate inducible proton re-entry into the mitochondrial matrix affecting ATP turnover as a protection mechanism against oxidative stress. Proton re-entry may be coupled to metabolite transport to allow for proton flux switching and optimal ATP turnover (PubMed:11171965, PubMed:33373220, PubMed:11278935) (By similarity). Regulates the use of glucose as a source of energy. Required for glucose-induced DRP1-dependent mitochondrial fission and neuron activation in the ventromedial nucleus of the hypothalamus (VMH). This mitochondrial adaptation mechanism modulates the VMH pool of glucose-excited neurons with an impact on systemic glucose homeostasis (By similarity). Regulates ROS levels and metabolic reprogramming of macrophages during the resolution phase of inflammation. Attenuates ROS production in response to IL33 to preserve the integrity of the Krebs cycle required for persistent production of itaconate and subsequent GATA3-dependent differentiation of inflammation-resolving alternatively activated macrophages (By similarity). Can unidirectionally transport anions including L-malate, L-aspartate and phosphate (PubMed:24395786). Does not mediate adaptive thermogenesis (By similarity)

The "UCP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UCP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets